Nucleosome assembly protein 1-like 5 (NAP1L5)

Nucleosome assembly protein 1-like 5 (NAP1L5) is a member of the NAP1L protein family, which are evolutionarily conserved histone chaperones[1][2][3]. These proteins assist in the assembly and disassembly of nucleosomes by mediating the incorporation and transport of histone variants during chromatin remodeling[1][2][3]. NAP1L5 is the most recently identified member and has the shortest peptide sequence (182 amino acids) among the NAP1L family[1][2]. It is expressed as a single exon gene and is notably identified as an imprinted gene in human liver malignancy[1][3]. NAP1L5 shows upregulation in models of cardiac hypertrophy, promoting nucleolar hypertrophy, ribosome assembly, and increased protein synthesis crucial for pathological cardiac growth[1][2]. In neurodegenerative diseases like Alzheimer’s, NAP1L5 is downregulated and overexpression can alleviate AD-like cellular pathology, potentially via the GSK3B/Wnt/β-catenin pathway[3]. While its family members have well-defined chaperone activities, the precise molecular and pathophysiological functions of NAP1L5 are still incompletely characterized[1][2][3]. There are no known drugs that directly target NAP1L5, nor are there established mechanisms of drug interaction or specific safety signals reported in the literature[1][2][3][4].

Other names

NAP1L5DRLMDown-regulated in liver malignancynucleosome assembly protein 1 like 5imprinted gene in liver cancer